Abstract
Editorials1 April 1985Niclosamide Therapy for Tapeworm InfectionsRICHARD D. PEARSON, M.D., ERIK L. HEWLETT, M.D.RICHARD D. PEARSON, M.D.Search for more papers by this author, ERIK L. HEWLETT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-4-550 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptNiclosamide [N-(2′-chloro-4′-nitrophenyl)-5-chlorosalicylamide] was developed at Bayer A. G. (1-3) and initially shown to be effective against Hymenolepis diminuta, the rat tapeworm, a cestode that occasionally infects humans. Subsequent studies in animals and humans showed that niclosamide was poorly absorbed and non-toxic after oral administration (2) and that it was active against a number of tapeworms that infect humans. Niclosamide is also used in veterinary practices and as a molluscicide.Niclosamide first became commercially available outside the United States in 1961 (Yomesan; Bayer A.G., Wuppertal, West Germany), but until recently it could be obtained in this country only as an investigational...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
